BridgeBio Pharma (BBIO) Osake Kurssi
BridgeBio Pharma Kurssi
Liikevaihto on kasvanut 52,1 % vuodessa viimeisten 6 vuoden aikana 502,08 M USD:een. BridgeBio Pharman nettomarginaali on nyt −145,3 %, noussut −806,9 %:sta muutama vuosi sitten. Analyytikoiden mediaanitavoitehinta on 106,50 USD, eli yli nykyhintaa 64,4 %. 29 analyytikosta 26 suosittaa ostoa — kokonaiskonsensus on Osta.
BridgeBio Pharma osakekurssi
BridgeBio Pharma liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset BridgeBio Pharma -osakkeesta
BridgeBio Pharma Inc is a biopharmaceutical company specializing in the development and commercialization of genetic medicines. The company aims to identify and advance therapies for diseases with clear genetic causes, leveraging its deep understanding of molecular pathways and human biology. BridgeBio Pharma Inc follows a diversified business model, which includes creating subsidiary companies focused on developing treatments for specific genetic diseases. These subsidiaries collaborate with academic institutions and industry partners to expedite the development of innovative therapies. By focusing on genetically driven diseases and utilizing a collaborative approach, BridgeBio Pharma Inc strives to bring transformative treatments to patients in need.
BridgeBio Pharma Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of BridgeBio Pharma Inc in the market include companies such as Amgen Inc, Gilead Sciences Inc, Biogen Inc, and Vertex Pharmaceuticals Incorporated.
BridgeBio Pharma Inc is a leading pharmaceutical company specializing in the development and commercialization of targeted therapies for genetic diseases and cancers. Founded in 2015, BridgeBio Pharma Inc has rapidly grown into a prominent player in the biotechnology industry. The company's mission is to identify and advance transformative medicines that address the unmet needs of patients with genetically driven conditions. With its innovative pipeline of candidates, BridgeBio Pharma Inc aims to make a meaningful impact on patients' lives. By leveraging its deep expertise in genetics and drug development, the company is poised to revolutionize the treatment landscape for various rare diseases and oncology indications.
BridgeBio Pharma Inc has achieved several significant milestones since its inception. The company has successfully developed a diverse pipeline of investigative compounds across multiple therapeutic areas, including genetically defined diseases and cancers. BridgeBio Pharma has also formed strategic partnerships with leading pharmaceutical companies to accelerate the development and commercialization of its promising candidates. Additionally, the company has received regulatory approvals for several of its therapeutics and has successfully advanced them into clinical trials. These milestones highlight BridgeBio Pharma's commitment to addressing unmet medical needs and advancing innovative therapies for patients around the world.
BridgeBio Pharma Inc is primarily present in the United States.
BridgeBio Pharma Inc represents a commitment to innovative solutions and transformative therapies. Guided by a strong corporate philosophy, the company focuses on addressing unmet medical needs and improving patient outcomes. BridgeBio Pharma Inc pioneers in developing targeted medicines for genetic diseases and cancers. With their dedication to scientific excellence, they identify potential drug candidates and accelerate their development through collaborations and partnerships. By leveraging cutting-edge research and technological advancements, BridgeBio Pharma Inc aims to positively impact the lives of patients and families affected by rare genetic disorders.
Analyytikot asettavat tällä hetkellä BridgeBio Pharma-osakkeelle keskimääräisen tavoitehinnan 107,92 USD (mediaani: 106,50 USD), mikä merkitsee +66,6 % viimeisimpään hintaan verrattuna. Konsensus perustuu 29 analyytikkoarvioon.
29 analyytikkoa arvioi tällä hetkellä BridgeBio Pharma-osaketta: 26 suosittaa ostoa, 3 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat BridgeBio Pharma-yhtiöltä 1,02 Mrd. USD liikevaihtoa ja −2,72 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla BridgeBio Pharma-osake noteerataan hintaan 57,80 EUR (64,77 USD).
BridgeBio Pharma-osake (BBIO) on listattuna 3 pörssissä, muun muassa: NASDAQ (BBIO), München (2CL.MU), Düsseldorf (2CL.DU).
BridgeBio Pharma Inc. is a biotechnology company focused on developing drugs for rare diseases. The company was founded in 2015 and is based in Palo Alto, California. Its business model is based on identifying and developing therapy approaches for rare diseases. BridgeBio works closely with researchers, academics, and other biotech companies to develop innovative therapies. It has a strong pipeline of drug candidates in preclinical and clinical studies. Flagship products include Infigratinib for FGFR2-gene defined cholangiocarcinoma and BBP-265 for ACADVL deficiency. BridgeBio has partnerships with major pharmaceutical companies such as Pfizer and Roche. It focuses on rare diseases, taking advantage of the limited treatment options and strong need in these patient populations. The company is funded through investments from venture capital firms and public institutions. It had a successful IPO in June 2019, raising nearly $350 million for pipeline development and financing teams working on new therapies. Overall, BridgeBio's business model is centered on identifying and developing therapies for rare diseases, with a strong pipeline and partnerships in place.
odotettu liikevaihto BridgeBio Pharma on 1,02 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto BridgeBio Pharma on −537,05 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
BridgeBio Pharma:n hinta-voitto-suhde (P/E) on tällä hetkellä −23,79. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan BridgeBio Pharma-osakkeen arvostusta.
BridgeBio Pharma:n hinta-myynti-suhde (P/S) on tällä hetkellä 12,52. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii BridgeBio Pharma-osakkeen arvostuskennuslukuna.
BridgeBio Pharma:n Eulpool-laatuscore on 3/10.
BridgeBio Pharma:n ISIN on US10806X1028. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
BridgeBio Pharma:n WKN on A2PLX7. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
BridgeBio Pharma:n ticker on BBIO. Tämä pörssinoteeraus käytetään BridgeBio Pharma-osakkeiden kauppaan pörssissä.
BridgeBio Pharma osake
BridgeBio Pharma vertaisryhmä
BridgeBio Pharma Ticker
BridgeBio Pharma FIGI
Kaikki tunnusluvut ja syvällinen analyysi BridgeBio Pharma:sta
Meidän osakeanalyysimme BridgeBio Pharma-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut BridgeBio Pharma:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: